Skip to main content

CORRECTION article

Front. Pharmacol., 07 October 2021
Sec. Experimental Pharmacology and Drug Discovery
Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.777914

Corrigendum: The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis via Modulating Multiple Signaling Pathways in Mice

This article is a correction to:

  1. The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis Via Modulating Multiple Signaling Pathways in Mice

    1. Read original article
Yongqiang Ai&#x;Yongqiang Ai1†Wei Shi&#x;Wei Shi1†Xiaobin Zuo&#x;Xiaobin Zuo1†Xiaoming Sun&#x;Xiaoming Sun1†Yuanyuan ChenYuanyuan Chen1Zhilei WangZhilei Wang1Ruisheng LiRuisheng Li2Xueai SongXueai Song3Wenzhang DaiWenzhang Dai1Wenqing MuWenqing Mu1Kaixin DingKaixin Ding1Zhiyong LiZhiyong Li1Qiang LiQiang Li1Xiaohe Xiao, Xiaohe Xiao1,3*Xiaoyan Zhan, Xiaoyan Zhan1,3*Zhaofang Bai, Zhaofang Bai1,3*
  • 1Department of Hepatology, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China
  • 2Research Center for Clinical and Translational Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
  • 3China Military Institute of Chinese Materia, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China

A corrigendum on
The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis via Modulating Multiple Signaling Pathways in Mice

by Ai, Y., Shi, W., Zuo, X., Sun, X., Chen, Y., Wang, Z., Li, R., Song, X., Dai, W., Mu, W., Ding, K., Li, Z., Li, Q., Xiao, X., Zhan, X., Bai, Z. (2021). Front. Pharmacol. 12:655531. doi: 10.3389/fphar.2021.655531

In the original article, there was a mistake in Figure 5 as published. The symbols (*, **, ***, ns) of statistic differences in Figures 5B–F were wrongly labeled. The wrongly labeled Figure 5 was uploaded by accident when submitting the corrections of proof. The corrected Figure 5 appears below.

FIGURE 5
www.frontiersin.org

FIGURE 5. A combination of SolB and WeD treatment dramatically inhibits hepatic fibrosis and injury in CCL4-induced hepatic fibrosis mice. (A) Images of livers from control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB(40 mg/kg) and WeD(20 mg/kg). Representative micrographs of liver H&E staining, Sirius red, Masson and α-SMA staining were shown. Scale bars represent 50 μm. (B–D) Quantitative results of Sirius red(B), Masson(C) and α-SMA(D) staining sections. (E) Serum level of hydroxyproline of control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB and WeD. (F) Quantitative PCR analysis of mRNA levels of α-SMA in livers from control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB and WeD. (G) Western blot analysis of Collagen1, p-Smad3, Smad2/3, p-IκBα, IκBα and GAPDH in livers from control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB and WeD. Data are expressed as Mean ± SD (n = 8 or 3 mice). Statistics differences were analyzed using One-way ANOVA followed by Tukey’s post hoc tes: *p < 0.05, **p < 0.01, ***p < 0.001. NS, no significance.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: schisandrol B, wedelolactone, hepatic fibrosis, combined pharmacotherapy, TGF-β1/Smads signaling pathway

Citation: Ai Y, Shi W, Zuo X, Sun X, Chen Y, Wang Z, Li R, Song X, Dai W, Mu W, Ding K, Li Z, Li Q, Xiao X, Zhan X and Bai Z (2021) Corrigendum: The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis via Modulating Multiple Signaling Pathways in Mice. Front. Pharmacol. 12:777914. doi: 10.3389/fphar.2021.777914

Received: 16 September 2021; Accepted: 21 September 2021;
Published: 07 October 2021.

Edited and reviewed by:

Salvatore Salomone, University of Catania, Italy

Copyright © 2021 Ai, Shi, Zuo, Sun, Chen, Wang, Li, Song, Dai, Mu, Ding, Li, Li, Xiao, Zhan and Bai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zhaofang Bai, baizf2008@hotmail.com; Xiaoyan Zhan, xyzhan123@163.com; Xiaohe Xiao, pharmacy_302@126.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.